Physician profile
Christopher Dunham
NPI 1508989732
$3,751.94
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,167 · 2024: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,726 · Education: $25.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,726.11 |
| Education | $25.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $825.73 | 2023-2024 | Cimzia |
| Amgen INC. | $747.03 | 2023-2024 | Enbrel, Otezla, Prolia |
| Abbvie INC. | $575.41 | 2023-2024 | |
| Lilly USA, LLC | $261.63 | 2023-2024 | Taltz |
| Pfizer INC. | $242.92 | 2023-2024 | |
| Organon LLC | $190.45 | 2023-2024 | Hadlima, Renflexis |
| Astrazeneca Pharmaceuticals LP | $140.40 | 2023-2024 | Saphnelo |
| Radius Health, INC. | $120.73 | 2023 | Tymlos |
| Mallinckrodt Hospital Products INC. | $106.34 | 2023-2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.23 | 2023-2024 | Ofev, Cyltezo |
| Genzyme Corporation | $73.43 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $53.96 | 2023-2024 | Orencia |
| Bioventus LLC | $49.19 | 2023 | Gelsyn-3 |
| Kyowa Kirin, INC. | $49.07 | 2023 | Crysvita |
| Mylan Institutional INC. | $40.82 | 2023 | Hulio |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $33.63 | 2023 | Krystexxa |
| Fresenius Kabi USA, LLC | $30.85 | 2023 | |
| Sandoz INC. | $27.46 | 2024 | Hyrimoz |
| Celltrion USA INC. | $25.83 | 2023 | Yuflyma |
| Ferring Pharmaceuticals INC. | $19.71 | 2024 | Euflexxa |
| Kiniksa Pharmaceuticals, LTD. | $15.93 | 2023 | Arcalyst |
| Teva Pharmaceuticals USA, INC. | $15.85 | 2023 | Truxima |
| Alexion Pharmaceuticals, INC. | $14.34 | 2023 | Strensiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Dunham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.